FORM PTO-1390 (REV. 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER Le A 33 846 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP00/05410 13 June 2000 (13.06.00) 25 June 1999 (25.06.99) TITLE OF INVENTION COMBINATION OF MTIP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS APPLICANT(S) FOR DO/EO/US GRUTZMANN, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. x have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. 🗴 A FIRST preliminary amendment. 14. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. 15. l la A change of power of attorney and/or address letter. 17.[7] A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. \square A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. Other items or information:1) Certificat f Mailing under 37 C.F.R. 1.10; Transmittal f Information Disclosur Stat m nt und r 37 C.F.R. 1.97(b);

4) Return Receipt P stcard.

3) Informati n Discl sur Citation (M difi d F rm PTO-1449) and r f rences cit d th reir

Dat f D posit: DEC 2 1 2001

Express Mail Label No.: ET386113230US

U.S. APPLICATION NO. 6F kpgwn 95 37 CFP 157 INTERNATIONAL APPLICATION NO. PCT/EP00/05410				-3/-2	ATTORNEY'S DOCKET NUMBER Le A 33 846	
21. X The following fees are submitted:					LCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):						
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO						
and International Search Report not prepared by the EPO or JPO \$1000.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)						
International preliminary examination fee (37 CFR 1.482) paid to USPTO						
and all claims satisfied provisions of PCT Article 33(1)-(4)						
ENTER APPROPRIATE BASIC FEE AMOUNT =					0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						
CLAIMS	NUMBER FILE		RATE	\$	00	
Total claims	12 - 20		x \$18.00	Ψ _	00	↓
Independent claims MULTIPLE DEPEN	- 3		x \$80.0084.00	9	.00	
MOLTIFLE DEPEN		(II applicable)	+ \$270.00280.00	40	0.00	
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						1
T - T - T - T - T - T - T - T - T - T -					00.00	
SUBTOTAL = Processing fee of \$130.00 for furnishing the English translation later than 20 30						
months from the earliest claimed priority date (37 CFR 1.492(f)).						
TOTAL NATIONAL FEE =					00.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						
TOTAL FEES ENCLOSED =					0.00	
					unt to be efunded:	\$
					charged:	\$
a. A check in the amount of \$ to cover the above fees is enclosed					<u> </u>	•
b. A duplicate copy of this sheet is enclosed. Please charge my Deposit Account No. 13-3372 in the amount of \$ 890.00 to cover the above fees.						
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any						
overpayment to Deposit Account No. 13-3372 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card						
information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO:						_
Jeffrey M. Greenman SIGNATUR					1 , / }\.	-7
Vice President, Patents and Licensing Bayer Corp ration 400 M rgan Lane NAME NAME					av	1
					-,	-\
31,018 REGISTRA				TION N	IUMBER	
			120.01101			

Attorn y's Docket No. Le A 33 846

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Grutzmann, et al.

Serial No.: National Stage Filing of PCT/EP00/05410

Filed: herewith

For: Combination of MTP Inhibitors and HMG-CoA Reductase Inhibitors and the Use Thereof

in Medicaments

BOX PCT Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the attached correspondence comprising:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
 Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];
- Preliminary Amendment;
- Original Combined Declaration and Power of Attorney;
- English Translation of the Application (35 U.S.C. 371(c)(2));
- Copy of the International Application as filed (35 U.S.C. 371(c)(2));
- Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein; and
- Return Receipt Post Card.

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET386113230US, addressed to:

Box PCT U.S. Patent and Trademark Office Box 2327 Arlington, Virginia 22202

DEC 2 1 2001

Date

Signature of Person Ce